

# Letter by Neumann et al Regarding Article, "Myostatin Regulates Energy Homeostasis in the Heart and Prevents Heart Failure"

## Citation for published version (APA):

Neumann, D., Luiken, J. J. F. P., Nabben, M., & Glatz, J. F. C. (2015). Letter by Neumann et al Regarding Article, "Myostatin Regulates Energy Homeostasis in the Heart and Prevents Heart Failure". *Circulation Research*, 116(10), E95-E96. <https://doi.org/10.1161/CIRCRESAHA.115.306463>

## Document status and date:

Published: 08/05/2015

## DOI:

[10.1161/CIRCRESAHA.115.306463](https://doi.org/10.1161/CIRCRESAHA.115.306463)

## Document Version:

Publisher's PDF, also known as Version of record

## Document license:

Taverne

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

# Letter to the Editor

Letters to the Editor will be published, if suitable, as space permits. They should not exceed 1000 words (typed double-spaced) in length and may be subject to editing or abridgment.

## Letter by Neumann et al Regarding Article, “Myostatin Regulates Energy Homeostasis in the Heart and Prevents Heart Failure”

To the Editor:

We read with great interest the article by Biesemann et al<sup>1</sup> in which the authors uncovered an important role of myostatin and myostatin-dependent signaling pathways in the heart for maintaining cardiac energy homeostasis and preventing cardiac hypertrophy. The study is impressive because of the use of a mouse model that allows myostatin inactivation in adult cardiomyocytes and the amount and quality of collected data. The authors observed that inactivation of myostatin triggers both a metabolic switch toward an insulin-independent increase of glycolysis and the onset of cardiac hypertrophy. This metabolic switch is argued to occur via the increased activity of the energy sensor AMP-activated kinase (AMPK).

The supposed causal role of AMPK deregulation in cardiac hypertrophy is based mostly on the use of compound C. Compound C is a widely used pharmacological inhibitor of AMPK with known off-target effects, such as potent inhibition of several other kinases (ie, phosphorylase kinase and MAP-kinase-interacting kinase).<sup>2</sup> Therefore, caution should be taken in deducing AMPK involvement from such pharmacological approach. Moreover, through genetic models and the use of pharmacological activators, AMPK has been established as an inhibitor rather than a stimulator of cardiac hypertrophy, cell growth and proliferation, thus pointing to AMPK activation as a beneficial response mechanism and potential therapeutic strategy for cardiac hypertrophy and failure.<sup>3,4</sup> Accordingly, we suggest that AMPK, in its function as an energy sensor, is more likely to react to the metabolic alterations induced by myostatin ablation. Whether AMPK activation is a crucial step in mediating the observed metabolic changes and cardiac hypertrophy can be further questioned. In fact, stimulation of AMPK activity in cardiomyocytes simultaneously upregulates glucose and fatty acid uptake as well as their utilization.<sup>5</sup> Hence, a shift toward glucose if mediated by AMPK would require an unknown mechanism.

The reported increase of glycogen synthase phosphorylation, as an established AMPK substrate, turns out as inhibitory phosphorylation at Ser641 that is targeted by GSK3 (glycogen synthase kinase 3), another important player in cardiac hypertrophy.<sup>6</sup> The AMPK-dependent phosphorylation of glycogen synthase occurs at serine 7 and is likewise inhibitory to this enzyme.<sup>7</sup> Hence, the p-GS data do not add to the proposed involvement of AMPK.

The authors identified TAK1 (transforming growth factor  $\beta$ -activated kinase 1) as an inhibitory kinase of AMPK, which is opposite to previous published findings. In particular, cardiac-specific overexpression of a dominant negative mutant established TAK1 as an AMPK-activating kinase in heart and produced a phenotype reminiscent to human Wolff–Parkinson–White syndrome.<sup>8</sup> It is difficult to reconcile these data with the Biesemann study.

In the discussion section, one further link is made to PRKAG2 cardiomyopathy, which is mentioned as mimicking aspects of the myostatin phenotype (which refers to myostatin deletion). It should be noted that most of the described PRKAG2 mutations on the molecular level cause a loss of function rendering AMPK insensitive to AMP, which nevertheless results in increased AMPK activity, glycogen storage, and cardiac hypertrophy.<sup>9</sup> The reason for upregulated AMPK activity in PRKAG2 mutants, since occurring in conjunction with lack of stimulation, remains unclear at present.

Instead or besides AMPK there may be a role for protein kinase D signaling in cardiac hypertrophy caused by myostatin ablation, as the authors have shown that transphosphorylation, and presumably activity, of this kinase is increased. In this respect, protein kinase D1 activation is known to induce a hypertrophic programming in the heart via phosphorylation of HDAC5 (histone deacetylase 5) followed by deinhibition of the hypertrophic transcription factor MEF2 (myocyte enhancer factor 2).<sup>10</sup> Furthermore, protein kinase D1 activation might explain the reported increases in glucose uptake and utilization, as this kinase seems to play a crucial role in GLUT4 (glucose transporter type 4) translocation without having effects on myocardial fatty acid uptake and utilization.<sup>11</sup> Accordingly, cardiospecific constitutively active protein kinase D1 overexpression in mice stimulates GLUT4 translocation and thereby causes a myocardial substrate shift toward glucose.<sup>12</sup>

In conclusion, cardiac AMPK activation is the safeguard, not the culprit causing cardiac hypertrophy, in contrast to the authors' view. Despite disagreement over data interpretation, cardiac myostatin overexpression acutely affects AMPK activation, as the authors have convincingly shown. Therefore, future work should elucidate the changed cardiac energetics leading to suppressed AMPK activation (the T172 phosphorylation status), such as determining enzyme activities by kinase assay and measurements of AMP/ATP ratios backed up by in vivo PCr/Cr determinations. The alterations of heart metabolism that were observed on myostatin ablation, in particular the shift to glucose, enhanced glucose uptake, glycolysis, and the resulting cardiac hypertrophy, rather correspond to known effects of AMPK loss of function. Hence, the presented putative explanatory mechanisms at least deserve further scientific discussion.

## Acknowledgements

The authors thank the members of the Department of Molecular Genetics for helpful discussions.

## Sources of Funding

Current Research in the laboratory of D. Neumann is funded by The Netherlands Foundation for Scientific Research (NWO) (VIDI grant number 864.10.007).

## Disclosures

None.

**Dietbert Neumann**  
**Joost J.F.P. Luiken**  
**Miranda Nabben**  
**Jan F.C. Glatz**

*Department of Molecular Genetics*  
*CARIM School for Cardiovascular Diseases*  
*Maastricht University*  
*Maastricht, The Netherlands*

## References

1. Biesemann N, Mandler L, Wietelmann A, Hermann S, Schäfers M, Krüger M, Boettger T, Borchardt T, Braun T. Myostatin regulates energy homeostasis in the heart and prevents heart failure. *Circ Res*. 2014;115:296–310. doi: 10.1161/CIRCRESAHA.115.304185.
2. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors: a further update. *Biochem J*. 2007;408:297–315. doi: 10.1042/BJ20070797.
3. Horman S, Beauloye C, Vanoverschelde JL, Bertrand L. AMP-activated protein kinase in the control of cardiac metabolism and remodeling. *Curr Heart Fail Rep*. 2012;9:164–173. doi: 10.1007/s11897-012-0102-z.
4. Kim TT, Dyck JR. Is AMPK the savior of the failing heart? *Trends Endocrinol Metab*. 2015;26:40–48. doi: 10.1016/j.tem.2014.11.001.
5. Schwenk RW, Luiken JJ, Bonen A, Glatz JF. Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. *Cardiovasc Res*. 2008;79:249–258. doi: 10.1093/cvr/cvn116.
6. Cheng H, Woodgett J, Maamari M, Force T. Targeting GSK-3 family members in the heart: a very sharp double-edged sword. *J Mol Cell Cardiol*. 2011;51:607–613. doi: 10.1016/j.yjmcc.2010.11.020.
7. Jørgensen SB, Nielsen JN, Birk JB, Olsen GS, Viollet B, Andreelli F, Schjerling P, Vaulont S, Hardie DG, Hansen BF, Richter EA, Wojtaszewski JF. The alpha2-5'AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. *Diabetes*. 2004;53:3074–3081. doi: 10.2337/diabetes.53.12.3074.
8. Xie M, Zhang D, Dyck JR, Li Y, Zhang H, Morishima M, Mann DL, Taffet GE, Baldini A, Khoury DS, Schneider MD. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. *Proc Natl Acad Sci U S A*. 2006;103:17378–17383. doi: 10.1073/pnas.0604708103.
9. Grahame Hardie D. AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. *J Intern Med*. 2014;276:543–559. doi: 10.1111/joim.12268.
10. Olson EN, Backs J, McKinsey TA. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. *Novartis Found Symp*. 2006;274:3–12.
11. Dirx E, Schwenk RW, Coumans WA, Hoebbers N, Angin Y, Viollet B, Bonen A, van Eys GJ, Glatz JF, Luiken JJ. Protein kinase D1 is essential for contraction-induced glucose uptake but is not involved in fatty acid uptake into cardiomyocytes. *J Biol Chem*. 2012;287:5871–5881. doi: 10.1074/jbc.M111.281881.
12. Dirx E, van Eys GJ, Schwenk RW, Steinbusch LK, Hoebbers N, Coumans WA, Peters T, Janssen BJ, Brans B, Vogg AT, Neumann D, Glatz JF, Luiken JJ. Protein kinase-D1 overexpression prevents lipid-induced cardiac insulin resistance. *J Mol Cell Cardiol*. 2014;76:208–217. doi: 10.1016/j.yjmcc.2014.08.017.